[ad_1]
Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)’s share price reached a new 52-week low during trading on Tuesday . The stock traded as low as $4.37 and last traded at $4.53, with a volume of 16981 shares changing hands. The stock had previously closed at $4.65.
Several equities badysts have commented on FOMX shares. HC Wainwright set a $11.00 price target on Foamix Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 8th. Cantor Fitzgerald started coverage on Foamix Pharmaceuticals in a report on Thursday, October 11th. They issued an “overweight” rating for the company. Zacks Investment Research raised Foamix Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 target price for the company in a report on Wednesday, September 19th. BidaskClub cut Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 9th. Finally, ValuEngine raised Foamix Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, July 2nd. One investment badyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $8.25.
The firm has a market capitalization of $253.04 million, a PE ratio of -2.60 and a beta of 1.92.
Foamix Pharmaceuticals (NASDAQ:FOMX) last issued its earnings results on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.10. Foamix Pharmaceuticals had a negative return on equity of 131.84% and a negative net margin of 2,085.71%. The business had revenue of $0.96 million during the quarter, compared to badysts’ expectations of $1.10 million. On average, equities badysts predict that Foamix Pharmaceuticals Ltd will post -1.64 EPS for the current fiscal year.
In other news, CEO David Domzalski sold 8,238 shares of the stock in a transaction that occurred on Wednesday, August 8th. The stock was sold at an average price of $5.68, for a total value of $46,791.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders sold 11,763 shares of company stock valued at $66,910. 3.30% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently modified their holdings of the company. Handelsbanken Fonder AB raised its holdings in shares of Foamix Pharmaceuticals by 64.1% in the 3rd quarter. Handelsbanken Fonder AB now owns 640,000 shares of the specialty pharmaceutical company’s stock worth $3,667,000 after buying an additional 250,000 shares in the last quarter. First Manhattan Co. grew its position in Foamix Pharmaceuticals by 1,664.3% during the 3rd quarter. First Manhattan Co. now owns 617,500 shares of the specialty pharmaceutical company’s stock worth $3,538,000 after acquiring an additional 582,500 shares during the last quarter. Orbimed Advisors LLC grew its position in Foamix Pharmaceuticals by 223.2% during the 2nd quarter. Orbimed Advisors LLC now owns 4,040,000 shares of the specialty pharmaceutical company’s stock worth $20,240,000 after acquiring an additional 2,790,000 shares during the last quarter. Senzar Asset Management LLC bought a new stake in Foamix Pharmaceuticals during the 2nd quarter worth approximately $338,000. Finally, Citadel Advisors LLC grew its position in Foamix Pharmaceuticals by 3,281.1% during the 2nd quarter. Citadel Advisors LLC now owns 501,621 shares of the specialty pharmaceutical company’s stock worth $2,513,000 after acquiring an additional 486,785 shares during the last quarter. 46.99% of the stock is owned by institutional investors and hedge funds.
Foamix Pharmaceuticals Company Profile (NASDAQ:FOMX)
Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus.
See Also: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps
Receive News & Ratings for Foamix Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and badysts’ ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
Source link
